Acrivon Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-01-01
- Employees
- 61
- Market Cap
- $284.3M
- Website
- http://acrivon.com
- Introduction
Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Acrivon Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT06667141
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Acrivon Therapeutics
- Target Recruit Count
- 390
- Registration Number
- NCT05548296
- Locations
- 🇺🇸
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸Alaska Women's Cancer Center, Anchorage, Alaska, United States
🇺🇸HonorHealth, Phoenix, Arizona, United States